Q2 EPS Estimates for Upstream Bio Decreased by William Blair

Upstream Bio, Inc. (NASDAQ:UPB) – William Blair cut their Q2 2025 earnings per share estimates for Upstream Bio in a report issued on Tuesday, May 6th. William Blair analyst M. Phipps now anticipates that the company will earn ($0.59) per share for the quarter, down from their previous forecast of ($0.42). The consensus estimate for Upstream Bio’s current full-year earnings is ($4.30) per share. William Blair also issued estimates for Upstream Bio’s Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($2.61) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.73) EPS, Q4 2026 earnings at ($0.57) EPS, FY2026 earnings at ($2.89) EPS, FY2027 earnings at ($2.35) EPS, FY2028 earnings at ($2.45) EPS and FY2029 earnings at ($2.62) EPS.

Upstream Bio (NASDAQ:UPB) last announced its earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.71 million.

Upstream Bio Trading Down 1.2 %

Shares of NASDAQ UPB opened at $8.73 on Thursday. Upstream Bio has a one year low of $5.14 and a one year high of $29.46. The firm’s 50 day simple moving average is $8.03 and its two-hundred day simple moving average is $13.58.

Institutional Trading of Upstream Bio

A number of institutional investors have recently modified their holdings of UPB. FMR LLC bought a new stake in shares of Upstream Bio during the 4th quarter valued at about $117,977,000. Orbimed Advisors LLC purchased a new stake in Upstream Bio in the fourth quarter worth about $93,603,000. Decheng Capital LLC bought a new stake in Upstream Bio during the 4th quarter valued at approximately $54,010,000. TCG Crossover Management LLC purchased a new position in shares of Upstream Bio in the 4th quarter valued at approximately $44,856,000. Finally, Enavate Sciences GP LLC purchased a new position in shares of Upstream Bio in the 4th quarter valued at approximately $40,438,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.